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Percutaneous Transvenous Mitral Annuloplasty
Initial Human Experience With a Novel Coronary Sinus Implant Device
Stefan Sack, MD; Philipp Kahlert, MD; Luc Bilodeau, MD; Luc A. Pie`rard, MD;
Patrizio Lancellotti, MD; Victor Legrand, MD; Jozef Bartunek, MD, PhD; Marc Vanderheyden, MD;
Rainer Hoffmann, MD; Patrick Schauerte, MD; Takahiro Shiota, MD; David S. Marks, MD;
Raimund Erbel, MD; Stephen G. Ellis, MD
Background—We assessed the safety and feasibility of permanent implantation of a novel coronary sinus mitral repair
device (PTMA, Viacor Inc).
Methods and Results—Symptomatic (New York Heart Association class 2 or 3) patients with primarily functional mitral
regurgitation (MR) were included. A diagnostic PTMA procedure was performed in the coronary sinus venous
continuity. MR was assessed and the PTMA device adjusted to optimize efficacy. If MR reduction (!1 grade) was
observed, placement of a PTMA implant was attempted. Implanted patients were evaluated with echocardiographic,
quality of life, and exercise capacity metrics. Nineteen patients received a diagnostic PTMA study. Diagnostic PTMA
was effective in 13 patients (MR grade 3.2!0.6 reduced to 2.0!1.0), and PTMA implants were placed in 9 patients.
Four devices were removed uneventfully (7, 84, 197, and 216 days), 3 for annuloplasty surgery due to observed PTMA
device migration and/or diminished efficacy. No procedure or device-related major adverse events with permanent
sequela were observed in any of the diagnostic or implant patients. Sustained reductions of mitral annulus septal-lateral
dimension from 3D echo reconstruction dimensions were observed (4.0!1.2 mm at 3 months).
Conclusions—Percutaneous implantation of the PTMA device is feasible and safe. Acute results demonstrate a possibly
meaningful reduction of MR in responding patients. Sustained favorable geometric modification of the mitral annulus
has been observed, though reduction of MR has been limited. The PTMA method warrants continued evaluation and
development. (Circ Cardiovasc Intervent. 2009;2:277-284.)
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Mitral regurgitation (MR) frequently accompanies heartfailure.1–3 Although discrete leaflet pathology may
induce pure MR and heart failure, often MR is functional and
occurs without leaflet abnormalities. Functional MR is a
consequence of ventricular geometric distortion, annular
dilatation, and frequently tethering of the leaflets4 and may
precipitate or accelerate ventricular enlargement, annular
dilation, and heart failure symptoms.5 In a graded fashion,
MR is an independent predictor of morbidity and mortality in
patients with ischemic heart disease and heart failure.6,7 MR
clinical presentation is also frequently dynamic and exagger-
ated by exertion, thus leading to underassessment of the disease
state severity by echocardiography performed at rest.8–12
Current therapeutic interventions to limit the impact of MR
include both medical and surgical therapies.13,14 Surgical
valve repair is performed via placement of an annuloplasty
ring and/or mitral leaflet-subvalvular apparatus repair or
mitral valve replacement.15,16 Current guidelines encourage
surgical therapy for patients with symptoms, atrial fibrilla-
tion/arrhythmias, pulmonary hypertension, or changes in left
ventricular function.17,18 Many patients who might otherwise
benefit from treatment are excluded because they are unsuit-
able for such highly invasive open chest surgery due to the
associated surgical morbidity and mortality.19,20 Similarly,
many patients with mild MR at the time of surgical revascu-
larization progress to significant MR after coronary artery
bypass grafting.21
Various investigators have proposed less invasive repair
techniques to interrupt the natural history of MR in ischemic
heart disease and heart failure.22–24 Current efforts include
approaches to directly clip25 the mitral leaflets or modify the
mitral annulus via the coronary sinus26,27 and various other
Received June 26, 2008; accepted April 20, 2009.
From the Department of Cardiology (S.S., P.K., R.E.), West German Heart Center, Essen, Germany; the Department of Medicine (L.B.), Montreal
Heart Institute, Montre´al, Canada; the Department of Cardiology (L.P., V.L., P.L.), University Hospital of Lie`ge, Lie`ge, Belgium; the Department of
Cardiology (R.H., P.S.), R-WTH University Hospital Aachen, Aachen, Germany; the Cardiovascular Center OLV Ziekenhuis (J.B., M.V.), Aalst,
Belgium; Medical College of Wisconsin (D.M.), Milwaukee, Wis; and Department of Cardiovascular Medicine (S.E., T.S.), Cleveland Clinic, Cleveland,
Ohio.
Correspondence to Stefan Sack, MD, Klinikum Schwabing, Sta¨dtisches Klinikum Mu¨nchen GmbH, Ko¨lner Platz 1, D-80804 Mu¨nchen, Germany.
E-mail stefan.sack@klinikum-muenchen.de
© 2009 American Heart Association, Inc.
Circ Cardiovasc Intervent is available at http://circinterventions.ahajournals.org DOI: 10.1161/CIRCINTERVENTIONS.109.855205
277
novel techniques.28 Preliminary data in both animal models
and initial, temporary human studies have demonstrated the
potential of the PTMA device (Viacor Inc, Wilmington,
Mass) and the method to reduce the mitral annular septal-
lateral dimension and limit MR.29,30 This report describes




Patients were enrolled in 4 European and 1 Canadian institution
between April 2006 and November 2007. The protocol was approved
by national regulatory bodies and local ethics committees. New York
Heart Association functional class 2 to 3 patients with heart failure
were screened for possible participation based on medical history
and echocardiographic findings. Eligible patients included those with
moderate to severe functional MR, graded 2" to 4", and a left
ventricular ejection fraction of 20% to 50%. Contraindications to
PTMA included organic mitral valve disease, leaflet prolapse,
significant renal dysfunction (Cr #2.3 mg/dL), presence of a
proximal coronary circumflex stent, and a left dominant coronary
circulation. Preprocedure evaluation included transthoracic echocar-
diography with 3D imaging of the mitral annulus, 6-minute walk,
and quality-of-life survey. The study’s primary end point was safety
(30-day major adverse cardiac event).
PTMA Device Description
The Viacor PTMA system uses 2 primary structural elements: a
multilumen PTFE (Teflon) PTMA catheter and Nitinol (nickel-
titanium alloy) PTMA treatment rods. The PTMA catheter is
provided in both diagnostic and implant versions. The PTMA system
has been described previously.31 The PTMA implant device incor-
porates an integral proximal titanium access hub to facilitate the
delivery and fix the position of the PTMA rods within the implant
system. The implant differs from the diagnostic device in that the
treatment section of the implant is fitted with an integral, nonabsorb-
able external polyester surgical suture winding to enhance the
stability of the PTMA implant system. The diagnostic and implant
PTMA rods are equivalent; each is formed from a single Nitinol wire
that is profiled to provide precise, incremental application of stiff-
ness to the posterior mitral annulus and thus reduce the septal-lateral
dimension of the valve, improve leaflet coaptation, and reduce MR.
Procedure
Interventional device placement was performed in the cardiac
catheterization laboratory after induction of general anesthesia.
Transesophageal echocardiography (TEE) was used to measure
quantitative procedural baseline MR and the septal-lateral annular
dimension. For the most recent 15 patients enrolled in the study, a
contrast enhanced, multidetector computed tomography (MDCT)
scan was obtained before the procedure, and the dataset selectively
rendered (M2S, West Lebanon, NH) and reviewed from the perspec-
tive of standard fluoroscopic viewing angles, both before the
catheterization procedure and then continuously throughout the case
in matched viewing angles. Arterial access was obtained for coro-
nary angiography by standard techniques. Percutaneous venous
access was obtained via the right or left subclavian vein. Access to
the coronary sinus was established using standard 8F coronary sinus
(CSG) sheaths (St Jude Apeel or Biotronik ScoutPro). After occlu-
sive venography to demonstrate course and patency of the venous
anatomy in multiple fluoroscopic views, a guide wire was advanced
into the descending anterior interventricular vein. If the descending
anterior interventricular vein could not be accessed, the case
was terminated.
The Viacor 7F, 3-lumen PTMA diagnostic multilumen catheter
was advanced over a 0.025-in or, in later cases, 0.035-in guide wire
through the CSG sheath and into the coronary sinus under fluoro-
scopic guidance. The PTMA catheter was advanced until the distal
radio-opaque marker was observed to have advanced 2 to 3 cm past
the great cardiac vein into the anterior interventricular vein. PTMA
diagnostic rods were progressively inserted into the PTMA diagnos-
tic catheter to increase and adjust the treatment effect on the mitral
annulus as observed by TEE with hemodynamic manipulation as
needed to standardize arterial blood pressure during anesthesia. Up
to 3 PTMA treatment rods were placed simultaneously within the
PTMA catheter. Rods of various stiffness and design were used to
apply stiffnesses of 100 to 600 g/cm selectively to the P2 segment of
the mitral valve Angiographic, ECG and echocardiographic param-
eters were continuously monitored and recorded. Ultimate device
size and position was determined by maximal reduction in the mitral
annular dimensions with accompanying reduction in MR. If no
treatment effect was observed via TEE with diagnostic PTMA, the
devices were withdrawn and the patient was recovered. If treatment
benefit was noted, and angiography verified no impingement on
coronary circulation or PTMA device instability, the diagnostic
catheter was exchanged for the implant PTMA catheter and rods. To
conclude the implant procedure, the titanium PTMA implant hub
was closed, sutured to subclavian fascia, the skin closed, and the
patient was recovered.
Table 1. Summary of PTMA Implant Feasibility Cases Grouped by Device and Protocol Evolution
Case Group Dates
Procedures





1 April to May 2006 3 1 1 Initial device
2 September 2006 to January 2007 9 6† 1 Enhanced Nitinol fatigue properties
CT screening/selective rendering analysis
Additional PTMA device stiffness profiles
3 March to June 2007 11 8 5 0.025-in OTW implant configuration
Increased stiffness PTMA rods
Implants placed just distal of CSO
4 September to November 2007 6 6‡ 2 0.035-in OTW implant; more trackable tip
Reduced size, adjustable implant hub
More proximal implant position target: CSO engagement
CT indicates computed tomography; OTW, over the wire; CSO, coronary sinus orifice.
*All implanted patients first underwent a PTMA diagnostic procedure immediately preceding the PTMA implant.
†Two patients receiving successful diagnostic PTMA evaluations in group 2 were implanted in later procedures with improved devices, one each in groups 3 and 4.
‡Two PTMA diagnostic evaluation patients in group 4 are active candidates for future PTMA implants.
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Postprocedural Evaluation
Patients continued the standard medical care for heart failure without
protocol directed changes. Echocardiography, clinical examination,
and laboratory assessments were performed at 24 hours post-
implantation and at %14, 30, 180, and 360 days. Three-dimensional
geometric tracing of the mitral valve annulus at end diastole from
echocardiographic volume datasets was performed using Tomtec 4D
Cardio-View (Tomtec Imaging Systems, GmbH, Germany) software
to assess changes in mitral annular geometry. Quality of life and
exercise tolerance were performed at 30 and 180 days. Echocardi-
ography was evaluated both by the enrolling centers and by the
echocardiography core laboratory (Cleveland Clinic, Cleveland, Ohio).
Quantitative echocardiography of TEE procedural images was also
performed by the enrolling centers during and after procedures.
Results
Feasibility cases were conducted in 4 groups beginning in
April 2006 and continuing through November 2007 as sum-
marized in Table 1. Although the trial design and device
description remained essentially constant, each successive
group of cases incorporated incremental technical enhance-
ments in the device itself and procedure sequence reflective
of first-in-man case experience with a new therapeutic device.
In case groups 1, 2, and 3, the stiffness and fatigue properties
of the Nitinol PTMA devices were modified to more opti-
mally match the requirements of the human anatomy. During
case groups 2, 3, and 4, changes to both the diagnostic and
implant devices were made to improve the guide wire
trackability of the distal tip to improve access to the descend-
ing anterior interventricular vein. Finally, in group 4, the
implant system was modified to permit up to 15 mm of linear
adjustment of the position of the PTMA rods within the
implant system via an adjustable proximal hub.
Clinical features of the 27 patients (29 procedures) evalu-
ated for PTMA are shown in Table 2. Age was 70.4!9.4
years. Fifteen (56%) of the patients were men. Sixteen
patients (59%) had an ischemic etiology of heart failure and
10 (37%) had undergone a prior coronary artery bypass
grafting procedure. Baseline echocardiographic features are
shown in Table 3. In the entire cohort, the left ventricular
ejection fraction was 35.6!10.4% with an left ventricular
end-diastolic diameter of 58.2!8.3 mm. The effective regur-
gitant orifice area was 0.21!0.12 cm2.
Figure 1. Procedural features and course.
Table 2. Clinical Features of Patients (n!27)
n %
Age, y 70.4!9.4
Age#70 y 14 52




Previous CABG 10 37
Previous PCI 8 30
Obstructive lung disease 5 22
Atrial fibrillation 10 37
NYHA functional class III 20 74
NYHA functional class II 7 26
BSA#1.85 (m2) (1.87!0.19) 14 52
CABG indicates coronary artery bypass graft; PCI, percutaneous coronary
intervention; BSA, body surface area; NYHA, New York Heart Association.
Table 3. Baseline Echocardiographic Features of
Patients (n!27)
LV ejection fraction, % 35.6!10.4
LV end-diastolic volume, mL 108.9!51
LV end-systolic volume, mL 161.1!57
LV end-diastolic diameter, mm 58.2!8.3
Mitral annular dimension A-P diastolic, mm 30!4.6
Mitral annular dimension A-P systolic, mm 35!4.5
Effective regurgitant orifice, cm2 0.21!0.12
Regurgitant volume, mL 32.5!190
LV indicates left ventricular; A-P, anteroposterior.
Table 4. Procedure Major Adverse Cardiac Event and







Emergent surgery 0 0
Subclavicular hematoma 1 3
Pneumonia 1 3
Transient renal dysfunction 1 3
PTMA implant device fracture/removal 1 3
Circumflex stent implantation 1 3
Pericardial effusion (CS access related; no PTMA) 1 3
MI indicates myocardial infarction; CS, centrum semiovale.
Sack et al Initial Human Implants of the Viacor Mitral 279
Procedural major adverse cardial events and significant
in-hospital complications are listed in Table 4. None of the
device or procedure-related events resulted in permanent
sequela. Several events are notable. After placement of the
first implant, protocol driven angiography at 60 minutes
postimplant suggested a possible circumflex abnormality
directly adjacent to the PTMA device without reduction in
TIMI grade flow. Intravascular ultrasound was performed.
During and subsequent to intravascular ultrasound abrupt
vessel closure ensued with ST elevation. The vessel was
treated with stent implantation without further clinical event
or myonecrosis. In all subsequent cases, including during
both diagnostic and implant PTMA, there have been no
observations of similar abnormalities or arterial impingement.
The one noted event of device fracture and removal also
occurred in the first implanted patient. The device was
observed via x-ray to have suffered an internal fracture
resulting in loss of treatment effect as observed by echo. The
device was percutaneously removed uneventfully under flu-
oroscopic observation and local anesthesia. The single epi-
sode of pericardial effusion occurred during attempts to
access the coronary sinus with a commercially available
guide wire. The PTMA device was not introduced, pericar-
diocentesis was performed, and the procedure terminated.
Patient recovery was uneventful.
Procedural features and course are shown in Figure 1. A
total of 29 catheterization laboratory procedures have been
performed in 27 patients. This figure represents the cumula-
tive PTMA experience with the design iterations of the
PTMA intention-to-implant device. Anatomy or technical
failure to place the diagnostic PTMA device occurred in
29.6% of patients prompting multiple changes in the PTMA
device and technique (Table 1). The overall success rate of
diagnostic PTMA occurred in 13 of 27 patients (48%). With
successful placement of the PTMA diagnostic device, MR
was successfully reduced in 13 of 19 patients (68%). Learn-
Figure 2. Fluoroscopic images recorded from a left anterior oblique caudal angulation showing the initial PTMA catheter placement
without treatment devices (A) and after introduction and optimal positioning of the PTMA Nitinol treatment stiffening rods (B). Echocar-
diographic images from procedural TEE show a midesophageal long-axis view at procedure baseline (C) and with the PTMA implant
device in place (D).
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ing curves with both technique and imaging were demon-
strated through the improved percentage of cases with suc-
cessful access and PTMA diagnostic procedures. The
diagnostic PTMA procedure time was 138!42 minutes for
the entire cohort of patients. The implant PTMA procedure
required 35!38 minutes. In 2 patients, the PTMA implant
was performed in a procedure separate from a successful
diagnostic PTMA demonstrating efficacious reduction in
MR. The overall 30-day success rate of implanted PTMA was
8 of 13 (62%) (Table 2).
Sample case fluoroscopic and echocardiographic images
are shown in Figure 2. The impact of the device on the mitral
annulus can be clearly seen with TEE echocardiography and
guides successful placement of the rods. A lateral x-ray of a
PTMA implant at 30 and 90 days is shown in Figure 3
demonstrating device stability. Despite efficacious diagnostic
PTMA and implant placement, 2 devices migrated suffi-
ciently to be readily observed via echo and x-ray. One of the
devices was observed via echo and chest x-ray to have
partially dislodged proximally from the coronary sinus,
whereas another was observed to have migrated distally
within the coronary sinus and great cardiac vein. Along with
a third patient with minimal efficacy, all 3 devices were
removed by percutaneous approach, and the patients subse-
quently underwent annuloplasty surgery.
Acute echo results as observed by TEE in 13 patients
undergoing diagnostic PTMA with all iterations of the PTMA
system are shown in Figure 4. Core laboratory echo compos-
ite MR grade progression for the implanted patients from
baseline through the latest available follow-up study is shown
in Figure 5, including patients who subsequently underwent
device removal and surgical mitral valve repair. Figure 6
demonstrates sustained effective remodeling and reduction of
the mitral annulus via tracing of the mitral annulus from 3D
echo datasets.
Discussion
This report summarizes the first-in-man clinical experience
with the PTMA device and the progression of design modi-
fications to improve clinical success and durability in small
cohorts of patients. In contrast to other coronary sinus devices
using active fixation with stents or other tissue anchors, the
PTMA method is based on the application of an elastic
bending deformation without the use of discrete anchors or
stents. The method is intended to atraumatically diffuse the
remodeling forces over the maximum available length of the
Figure 3. Lateral x-rays taken at 30 and 90 days showing position and shape of the PTMA implant device.


















Figure 4. Baseline (MR grade 3.2!0.6) and best diagnostic pro-
cedure result (2.0!1.0) for 13 of the 19 diagnostic PTMA cases.
In the remaining 6 cases, TEE data were unavailable or unus-
able, primarily due to either image quality or hemodynamic vari-
ations; in 4 of the 6 cases, PTMA was considered ineffective,
and in the remaining 2 cases, only modest impact on MR was
observed.
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coronary venous continuity so as to minimize the likelihood
of arterial impingement or tissue erosion. Given the known
geometric complexities of the relevant mitral anatomy, the
PTMA clinical and technical approach is intended to allow
for iterative observation, learning, and device development.
Deflection of the device and the anatomy can be observed via
echocardiography and fluoroscopy, combined with MDCT
data, providing quantified input data to guide improvement of
the device characteristics. These principles have been extensively
modeled in relevant, though imperfect, animal models.29,30
Procedural and Implant Considerations
As has been previously reported, coronary venous anatomy
and the adjacent mitral apparatus are highly variable.32,33 The
primary end point for this feasibility study is safety; proce-
dure decisions were thus taken with considerable caution. As
the device is removable at any point, in the event of clinical
uncertainty, procedures were discontinued and no implant
devices placed.
Variability in the anatomy of the coronary venous system,
including tortuosity and narrow diameters, and also the
structural interrelation with the mitral apparatus, was appre-
ciated to impact both deliverability and stability of the PTMA
device. Retrograde venography is limited in its utility in
reliably guiding anterior vein subselection. Multidetector
computed tomography utilization in screening to demonstrate
continuity of the coronary venous system and coregistration
with fluoroscopic images improved technical success and
proved a valuable asset to the procedure.34,35 Successive
device iterations improved PTMA device deliverability, par-
ticularly the most recent change to 0.035-in guide wire
compatibility on the diagnostic and implant devices.
The implants that have achieved stable results chronically
as shown in Figure 6 were placed somewhat distal of the
CSO, thus sacrificing maximum geometric efficacy for
chronic stability. Current device improvements are directed
toward adjusting the stabilizing properties of the PTMA
system to facilitate increased geometric efficacy with a stable
device.
Arterial impingement with coronary sinus mitral repair
devices has been a significant concern raised by multiple
authors.23–27,32 We have only experienced the one described
event treated with circumflex stenting. No evidence of arterial
impingement was observed in any of the subsequent cases in
this cohort. This result may be due to the design of PTMA
device, which is exerting generally diffuse and outboard
pressure in the vicinity of typical circumflex coronary cross-
over. Given the close relationship and highly variable nature
of the venous and arterial courses and the close proximity and
significant elastic stiffness of the PTMA device, possible arterial
interaction will continue to be carefully evaluated both during
screening diagnostic and interventional procedures.
PTMA requires successful long-term engagement of the
coronary venous continuity relying on the structural integrity of
the PTMA nitinol rods and anatomic stability of the PTMA
device for long-term effect. Initial results from other mitral
annular remodeling devices have highlighted the concerns
regarding the durability challenges for structural implants
placed in the coronary venous continuity,26 as have the results
for surgical annuloplasty36,37 and biventricular pacing.38,39
The first PTMA implant was accompanied by Nitinol fracture
within the first 72 hours requiring explant. Fatigue and design
properties of the Nitinol were modified as were the durability
























Figure 5. Core laboratory composite TTE echo grading for the 9
patients receiving PTMA implants. Patient v-04-008 was graded
2 to 3" baseline by center-administered TEE examination.
PTMA implants in patients v-07-002, v-05-004, and v-05-005
were uneventfully removed percutaneously before annuloplasty
surgery. In patients v-07-002 and v-05-005, the PTMA device
was observed via echo and fluoroscopy to have migrated out of
the implanted position within the venous continuity.
Figure 6. Core laboratory tracings of the mitral annulus and leaflet line of coaptation from 3D echo data sets recorded at preprocedure
baseline and follow-up time points noted from patients with PTMA implants still observed by x-ray to be in place. Actual tracings are
full 3D datasets that also capture full contour information (eg, the “saddle shape” character of the annulus).
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test criteria and implant procedures. Subsequent long-term
implants have not evidenced any structural failures.
Evidence for Effect
In this initial series, particularly in cases where the patient
characteristics and device placement were favorable, significant
acute geometric reductions of mitral annular septal-lateral di-
mension and associated MR have been observed. Surgical
experience suggests that a septal-lateral annular reduction of
at least 8 mm is typically required for a successful repair in a
straightforward case.28,40 Multiple cases in this series have
acutely demonstrated corrections of this magnitude (Figure
3). However, the aggregate sustained reduction of the septal-
lateral dimension of the mitral annulus (Figure 6) has been
less than the typical surgical correction. Not surprisingly, the
associated late reductions of MR have been similarly modest.
Further examination of the clinical efficacy of this anatomic
effect as correlated to MR, chamber volumes, and clinical
outcomes requires further study because the clinical efficacy
of a partial correction may have limited benefit in a broad
range of patients. Thus, speculation as to the clinical impact
of the PTMA device in its early form is premature.
Study Limitations
The number of patients enrolled so far has been small and the
iterative nature of the investigation limits the generalizability
of the results. The protocol and device continues to undergo
fundamental improvements. Long-term efficacy and safety
remain unknown, including implications for subsequent pro-
cedures such as cardiac pacing and retrograde cardioplegia,
although successful mitral annular surgery after PTMA im-
plant demonstrates PTMA does not appear to limit surgical
options for patients.
Conclusions
This initial case series suggests that it is feasible and safe to
access and geometrically modify the mitral annulus with this
fully reversible, implantable coronary sinus device. The
initial safety results are acceptable. The magnitude of treat-
ment effect observed in implanted patients likely must be
increased to provide a significant clinical benefit for a meaning-
ful subgroup of patients. This experience warrants further
investigation to optimize treatment effect and elucidate the
clinical impact on patients with functional MR.
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